LXR are an attractive pharmacological target for regulating brain Aβ levels, but as specific agents for neurodegenerative diseases, agonists should be designed to penetrate the BBB and brain specificity, thereby avoiding systemic distribution, and are therefore preferred for LXRβ isomer specific ligands [22]. This evidence concerns the gene NR1H2 and neurodegenerative disease.